This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Matria Mashed by Contract Loss

Matria (MATR - Get Report) has suffered a major relapse.

Just as the healthcare company appeared to be getting back on its feet, Matria announced that its big contract with Wellmark -- meant to validate its ambitious acquisition of CorSolutions -- has been canceled. The company's stock, which hit a 52-week high of $32.49 a share just last week, slid 6% on Wednesday to $29.44.

For its part, Matria said that it has reached a mutual agreement with Wellmark to terminate the contract and that it foresees no financial hit this year. Still, Matria has been touting that deal for some time. The arrangement called for Matria to provide disease management services to a major health plan -- expanding the company's reach well beyond its core employer-based business -- and promised significant growth opportunities down the road.

Wall Street clearly seemed stunned by the development. After all, analysts have been counting on Matria's giant contract with Wellmark to start paying off handsomely and help the company hit its aggressive financial targets going forward.

To be fair, however, Matria itself stopped short of offering the reassurance that analysts were seeking when questioned about the company's relationship with Wellmark six weeks ago.

"We're working hard to enroll those people, to reach out to them with additional accounts," President Richard Hassett stated during April's first-quarter conference call. But "I think that, consistent with the lesson we learned at this time last year -- when one of our real marquee Fortune 20 accounts was up for renewal and we answered a lot of very specific questions, and that client sort of slapped us on the wrist -- we announced that we were going to be very constrained with respect to getting into details on specific clients.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
MATR $6.91 1.30%
AAPL $131.36 -0.97%
FB $81.10 -0.99%
GOOG $554.49 -0.16%
TSLA $230.50 -0.45%


DOW 18,095.52 +57.55 0.32%
S&P 500 2,111.92 +3.00 0.14%
NASDAQ 5,054.8820 -5.3640 -0.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs